Synmosa Biopharma Corporation (TPEX: 4114)
Taiwan
· Delayed Price · Currency is TWD 33.30
-0.15 (-0.45%)
Dec 20, 2024, 1:30 PM CST
Synmosa Biopharma Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 5,375 | 5,140 | 4,386 | 3,235 | 3,038 | 2,680 | Upgrade
|
| Revenue | 5,375 | 5,140 | 4,386 | 3,235 | 3,038 | 2,680 | Upgrade
|
| Revenue Growth (YoY) | 6.24% | 17.19% | 35.59% | 6.47% | 13.37% | 13.40% | Upgrade
|
| Cost of Revenue | 3,068 | 3,021 | 2,560 | 1,950 | 1,905 | 1,784 | Upgrade
|
| Gross Profit | 2,308 | 2,120 | 1,827 | 1,285 | 1,133 | 895.7 | Upgrade
|
| Selling, General & Admin | 1,340 | 1,287 | 1,148 | 883.58 | 817.24 | 786.25 | Upgrade
|
| Research & Development | 246.07 | 210.91 | 215.28 | 214.37 | 159.53 | 211.72 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -2 | 1.07 | Upgrade
|
| Operating Expenses | 1,590 | 1,503 | 1,366 | 1,099 | 983.56 | 1,002 | Upgrade
|
| Operating Income | 717.19 | 616.81 | 460.71 | 186.74 | 149.51 | -106.18 | Upgrade
|
| Interest Expense | -57.63 | -67.19 | -59.5 | -51.97 | -52.82 | -54.37 | Upgrade
|
| Interest & Investment Income | 26.16 | 16.32 | 7.18 | 3.43 | 4.26 | 4.37 | Upgrade
|
| Earnings From Equity Investments | -11.93 | -10.33 | -16.56 | -16.4 | -1.54 | -11.84 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.89 | 2.56 | 8.99 | 0.8 | 2.84 | -0.87 | Upgrade
|
| Other Non Operating Income (Expenses) | 23.6 | 23.02 | 49.71 | 11.66 | -4.1 | 11.65 | Upgrade
|
| EBT Excluding Unusual Items | 699.27 | 581.2 | 450.53 | 134.25 | 98.14 | -157.25 | Upgrade
|
| Impairment of Goodwill | -8.79 | -8.79 | -7.27 | -6 | -7.54 | -4 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.1 | 30.5 | 12.57 | 4.72 | 247 | 0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.35 | 0.92 | 281.72 | 11.86 | 0.68 | 0.82 | Upgrade
|
| Asset Writedown | -2.31 | -2.07 | -7.95 | -2.21 | -36.79 | -13 | Upgrade
|
| Other Unusual Items | -0.19 | -0.2 | -4.59 | 11.26 | 196.16 | 28.77 | Upgrade
|
| Pretax Income | 696.73 | 601.56 | 725.01 | 153.89 | 497.65 | -144.61 | Upgrade
|
| Income Tax Expense | 185.64 | 196.39 | 106.13 | 37.81 | 23.04 | -1.95 | Upgrade
|
| Earnings From Continuing Operations | 511.09 | 405.17 | 618.89 | 116.08 | 474.6 | -142.66 | Upgrade
|
| Minority Interest in Earnings | 206.98 | 189.66 | 180.21 | 187.79 | 163.51 | 189.75 | Upgrade
|
| Net Income | 718.07 | 594.83 | 799.09 | 303.86 | 638.11 | 47.09 | Upgrade
|
| Net Income to Common | 718.07 | 594.83 | 799.09 | 303.86 | 638.11 | 47.09 | Upgrade
|
| Net Income Growth | 22.85% | -25.56% | 162.98% | -52.38% | 1255.09% | -89.07% | Upgrade
|
| Shares Outstanding (Basic) | 420 | 406 | 391 | 394 | 384 | 352 | Upgrade
|
| Shares Outstanding (Diluted) | 422 | 408 | 392 | 395 | 386 | 352 | Upgrade
|
| Shares Change (YoY) | 5.55% | 3.87% | -0.79% | 2.35% | 9.76% | -9.42% | Upgrade
|
| EPS (Basic) | 1.71 | 1.46 | 2.04 | 0.77 | 1.66 | 0.13 | Upgrade
|
| EPS (Diluted) | 1.71 | 1.46 | 2.04 | 0.77 | 1.65 | 0.13 | Upgrade
|
| EPS Growth | 17.23% | -28.13% | 166.09% | -53.73% | 1135.06% | -87.93% | Upgrade
|
| Free Cash Flow | 491.07 | 304.89 | 500.95 | 361.81 | 100 | -228.25 | Upgrade
|
| Free Cash Flow Per Share | 1.16 | 0.75 | 1.28 | 0.91 | 0.26 | -0.65 | Upgrade
|
| Dividend Per Share | 0.545 | 0.545 | 0.499 | 0.383 | 0.202 | - | Upgrade
|
| Dividend Growth | 9.30% | 9.30% | 30.35% | 89.37% | - | - | Upgrade
|
| Gross Margin | 42.93% | 41.24% | 41.64% | 39.73% | 37.29% | 33.42% | Upgrade
|
| Operating Margin | 13.34% | 12.00% | 10.50% | 5.77% | 4.92% | -3.96% | Upgrade
|
| Profit Margin | 13.36% | 11.57% | 18.22% | 9.39% | 21.00% | 1.76% | Upgrade
|
| Free Cash Flow Margin | 9.14% | 5.93% | 11.42% | 11.18% | 3.29% | -8.52% | Upgrade
|
| EBITDA | 1,028 | 927.91 | 760.78 | 477.09 | 437.99 | 141.8 | Upgrade
|
| EBITDA Margin | 19.12% | 18.05% | 17.34% | 14.75% | 14.42% | 5.29% | Upgrade
|
| D&A For EBITDA | 310.78 | 311.1 | 300.08 | 290.35 | 288.48 | 247.97 | Upgrade
|
| EBIT | 717.19 | 616.81 | 460.71 | 186.74 | 149.51 | -106.18 | Upgrade
|
| EBIT Margin | 13.34% | 12.00% | 10.50% | 5.77% | 4.92% | -3.96% | Upgrade
|
| Effective Tax Rate | 26.64% | 32.65% | 14.64% | 24.57% | 4.63% | - | Upgrade
|
| Revenue as Reported | - | - | - | - | - | 2,680 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.